

Laura Rosinol Dachs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2170487/publications.pdf>

Version: 2024-02-01

169
papers

11,562
citations

87888

38
h-index

29157

104
g-index

171
all docs

171
docs citations

171
times ranked

9319
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their Influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e241-e249.	0.4	2
2	Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. British Journal of Haematology, 2022, 196, 649-659.	2.5	6
3	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. Leukemia and Lymphoma, 2022, 63, 984-990.	1.3	3
4	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2598-2609.	7.0	14
5	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Advances, 2022, 6, 3234-3239.	5.2	18
6	Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer Journal, 2022, 12, 45.	6.2	57
7	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	13
8	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 68.	6.2	8
9	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal, 2022, 12, 76.	6.2	5
10	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplantation and Cellular Therapy, 2022, 28, 489.e1-489.e9.	1.2	7
11	A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3) Tj ETQq1 1 0.784314mgBT /Over	1.6	2
12	Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, e20028-e20028.	1.6	2
13	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	1.6	40
14	Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.. Journal of Clinical Oncology, 2022, 40, 8033-8033.	1.6	2
15	Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2022, 40, 8035-8035.	1.6	4
16	Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. British Journal of Haematology, 2021, 193, 181-187.	2.5	20
17	Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. British Journal of Haematology, 2021, 193, 299-306.	2.5	5
18	Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. Leukemia and Lymphoma, 2021, 62, 125-135.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
20	Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. <i>Cancers</i> , 2021, 13, 2055.	3.7	5
21	Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. <i>American Journal of Kidney Diseases</i> , 2021, 78, 755-759.	1.9	4
22	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8026-8026.	1.6	5
23	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
24	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8042-8042.	1.6	5
25	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 619.e1-619.e8.	1.2	15
26	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. <i>Blood</i> , 2021, 138, 1901-1905.	1.4	23
27	Teclistamab, a B-cell maturation antigen- α -CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet, The</i> , 2021, 398, 665-674.	13.7	138
28	Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2904-2910.	2.4	7
29	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021, 100, 2997-3005.	1.8	2
30	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. <i>Cancers</i> , 2021, 13, 4924.	3.7	11
31	Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. <i>Cancers</i> , 2021, 13, 5131.	3.7	8
32	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. <i>Frontiers in Immunology</i> , 2021, 12, 792609.	4.8	3
33	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	1.4	7
34	Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2837-2837.	1.4	8
35	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 1596-1596.	1.4	0
36	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	1.4	29

#	ARTICLE	IF	CITATIONS
37	Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2021, 138, 552-552.	1.4	2
38	Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial. Blood, 2021, 138, 466-466.	1.4	19
39	Prognostic Impact of <i>MYD88</i> L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia. Blood, 2021, 138, 462-462.	1.4	3
40	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
41	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
42	Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. Bone Marrow Transplantation, 2020, 55, 461-463.	2.4	3
43	Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. Bone Marrow Transplantation, 2020, 55, 603-612.	2.4	33
44	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica, 2020, 105, 201-208.	3.5	48
45	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. Blood Advances, 2020, 4, 6023-6033.	5.2	15
46	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	7.2	26
47	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. Bone Marrow Transplantation, 2020, 55, 2270-2278.	2.4	9
48	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 4688-4698.	7.0	30
49	Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1565-1574.	1.3	8
50	Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. Bone Marrow Transplantation, 2020, 55, 1264-1271.	2.4	21
51	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	4.1	11
52	A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. Bone Marrow Transplantation, 2020, 55, 965-973.	2.4	15
53	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Journal of Medical Genetics, 2020, 57, 258-268.	3.2	18
54	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3

#	ARTICLE	IF	CITATIONS
55	The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrology, 2020, 21, 111.	1.8	18
56	Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance. Blood, 2020, 136, 5-6.	1.4	2
57	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 27-27.	1.4	51
58	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	1.4	24
59	Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).. Journal of Clinical Oncology, 2020, 38, 100-100.	1.6	37
60	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).. Journal of Clinical Oncology, 2020, 38, 8512-8512.	1.6	15
61	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE, 2020, 15, e0241778.	2.5	5
62	Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma. Blood, 2020, 136, 5-6.	1.4	0
63	Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2281-2286.	2.0	14
64	Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 97-98.	3.0	0
65	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood, 2019, 134, 1337-1345.	1.4	148
66	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplantation, 2019, 54, 1295-1303.	2.4	6
67	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood, 2019, 133, 2664-2668.	1.4	11
68	Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 1703-1712.	2.0	13
69	Pomalidomide+dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. European Journal of Haematology, 2019, 102, 389-394.	2.2	21
70	Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets. Blood, 2019, 134, 4355-4355.	1.4	2
71	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. Blood, 2019, 134, 506-506.	1.4	6
72	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 581-581.	1.4	14

#	ARTICLE	IF	CITATIONS
73	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549.	1.4	1
74	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 1852-1852.	1.4	1
75	Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 79-85.	3.0	17
76	Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. <i>Leukemia</i> , 2018, 32, 1427-1434.	7.2	48
77	Single Antigenâ€Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1196-1202.	2.0	50
78	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1541-1547.	2.4	20
79	Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. <i>Journal of Immunology</i> , 2018, 200, 2581-2591.	0.8	19
80	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. <i>PLoS ONE</i> , 2018, 13, e0203392.	2.5	18
81	The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. <i>Leukemia</i> , 2018, 32, 2082-2094.	7.2	1
82	Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2088-2093.	2.0	11
83	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	3.5	13
84	Patientâ€Reported healthâ€related quality of life from the phase III TOURMALINEâ€MM1 study of ixazomibâ€lenalidomideâ€dexamethasone versus placeboâ€lenalidomideâ€dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	4.1	41
85	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67
86	Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Microenvironment (TIME) of Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 4436-4436.	1.4	1
87	VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study. <i>Blood</i> , 2018, 132, 126-126.	1.4	13
88	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 3245-3245.	1.4	17
89	Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. <i>Blood</i> , 2018, 132, 112-112.	1.4	3
90	Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor. <i>Blood</i> , 2018, 132, 4503-4503.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58
92	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. <i>Haematologica</i> , 2017, 102, 1099-1104.	3.5	81
93	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 547-560.	2.5	48
94	Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1161-1168.	1.3	56
95	Renal outcomes of autologous stem cell transplantation among patients with light-chain amyloidosis: a single centre Spanish experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 70-71.	3.0	0
96	Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1269-1275.	2.0	3
97	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	1.3	22
98	Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 238-245.	3.0	5
99	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in <i>in vitro</i> and <i>in vivo</i> models of multiple myeloma by blockade of Ikaros and MYC signaling. <i>Haematologica</i> , 2017, 102, 1776-1784.	3.5	43
100	Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 849-851.	2.5	11
101	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	1.6	248
102	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1127-1136.	10.7	128
103	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. <i>Blood</i> , 2016, 127, 1151-1162.	1.4	68
104	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	1.4	129
105	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
106	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
107	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
108	Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e71-e77.	0.4	17

#	ARTICLE	IF	CITATIONS
109	Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1456-1462.	12.1	56
110	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3283-3283.	1.4	2
111	Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. <i>Blood</i> , 2016, 128, 3308-3308.	1.4	2
112	Response to Proteasome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. <i>Blood</i> , 2016, 128, 3436-3436.	1.4	1
113	The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators. <i>Blood</i> , 2016, 128, 5688-5688.	1.4	1
114	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8045-8045.	1.6	1
115	BET Bromodomain Blockade Enhances Ikaros Inhibition By Lenalidomide Therapy Providing Additional Activity in In Vitro and In Vivo Models of Multiple Myeloma. <i>Blood</i> , 2016, 128, 308-308.	1.4	0
116	Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5709-5709.	1.4	1
117	How I treat relapsed myeloma. <i>Blood</i> , 2015, 125, 1532-1540.	1.4	31
118	Extramedullary disease in multiple myeloma in the era of novel agents. <i>British Journal of Haematology</i> , 2015, 169, 763-765.	2.5	21
119	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	5.7	48
120	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
121	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
122	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015, 126, 1844-1844.	1.4	5
123	Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years. <i>Blood</i> , 2015, 126, 1848-1848.	1.4	2
124	Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials. <i>Blood</i> , 2015, 126, 19-19.	1.4	4
125	Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials. <i>Blood</i> , 2015, 126, 2962-2962.	1.4	1
126	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	1.4	8

#	ARTICLE	IF	CITATIONS
127	Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hybridization (FISH). Blood, 2015, 126, 4243-4243.	1.4	2
128	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250.	1.4	27
129	Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study. Blood, 2015, 126, 721-721.	1.4	12
130	What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? the Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. Blood, 2015, 126, 725-725.	1.4	1
131	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). Blood, 2015, 126, 729-729.	1.4	3
132	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). Blood, 2015, 126, 731-731.	1.4	8
133	Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.. Journal of Clinical Oncology, 2015, 33, 8509-8509.	1.6	14
134	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. Journal of Clinical Oncology, 2015, 33, 8525-8525.	1.6	2
135	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget, 2015, 6, 1874-1883.	1.8	42
136	Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 2963-2963.	1.4	0
137	Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution. Blood, 2015, 126, 4395-4395.	1.4	0
138	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. Blood, 2015, 126, 4192-4192.	1.4	0
139	The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients. Blood, 2015, 126, 4181-4181.	1.4	2
140	Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. Blood, 2015, 126, 2955-2955.	1.4	0
141	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
142	Initial treatment of transplant-eligible patients in multiple myeloma. Expert Review of Hematology, 2014, 7, 43-53.	2.2	14
143	Issues of front-line therapy for multiple myeloma – the standard of care. Leukemia and Lymphoma, 2014, 55, 1959-1961.	1.3	1
144	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	1.4	380

#	ARTICLE	IF	CITATIONS
145	Long Term Follow-up on the Treatment of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. Blood, 2014, 124, 3465-3465.	1.4	6
146	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. Blood, 2014, 124, 79-79.	1.4	15
147	Time to Next Treatment Is Response Dependent and Treatment Independent Based on Evidence from RCTs in Stem Cell Transplantation Eligible Multiple Myeloma Patients. Blood, 2014, 124, 2122-2122.	1.4	0
148	Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity. Blood, 2014, 124, 5785-5785.	1.4	0
149	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq1 1 0.784314 rgBT /Overlo 10.7 219	1.4	0
150	Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM). Blood, 2013, 122, 2155-2155.	1.4	3
151	Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). Blood, 2013, 122, 3187-3187.	1.4	14
152	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2013, 122, 403-403.	1.4	4
153	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	1.4	56
154	Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM). Blood, 2013, 122, 3188-3188.	1.4	1
155	Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution. Blood, 2013, 122, 3132-3132.	1.4	0
156	Allogeneic Stem-Cell Transplantation In Multiple Myeloma In Real Practice: Long-Term Results From a Single Institution. Blood, 2013, 122, 5524-5524.	1.4	0
157	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica, 2012, 97, 616-621.	3.5	19
158	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	1.4	429
159	SMM: toward better predictors of progression. Blood, 2008, 111, 479-480.	1.4	0
160	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood, 2008, 112, 3591-3593.	1.4	247
161	Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. Mayo Clinic Proceedings, 2007, 82, 428-434.	3.0	76
162	Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.. Blood, 2007, 110, 729-729.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.. Blood, 2006, 108, 3086-3086.	1.4	3
164	Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. British Journal of Haematology, 2005, 130, 729-732.	2.5	40
165	Bortezomib-Induced Severe Hepatitis in Multiple Myeloma. Archives of Internal Medicine, 2005, 165, 464.	3.8	42
166	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	3.2	34
167	Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica, 2004, 89, 832-6.	3.5	100
168	Hypercalcemia as the Presenting Feature of T-Cell Lymphoid Blast Crisis of Ph-Positive Chronic Myeloid Leukemia. Leukemia and Lymphoma, 2001, 41, 203-206.	1.3	9
169	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	2.5	73